Moderna (MRNA) to Release Earnings on Thursday

Moderna (NASDAQ:MRNA) is set to post its quarterly earnings results before the market opens on Thursday, May 2nd. Analysts expect Moderna to post earnings of ($3.36) per share for the quarter. Moderna has set its FY 2024 guidance at EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm’s quarterly revenue was down 44.9% compared to the same quarter last year. During the same quarter last year, the firm earned $3.61 earnings per share. On average, analysts expect Moderna to post $-8 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Moderna Price Performance

MRNA stock opened at $108.85 on Thursday. The business has a fifty day moving average of $101.85 and a two-hundred day moving average of $93.64. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. The stock has a market cap of $41.68 billion, a price-to-earnings ratio of -8.77 and a beta of 1.62. Moderna has a 52-week low of $62.55 and a 52-week high of $142.79.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 647 shares of the business’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at approximately $406,651. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $103.38, for a total value of $1,550,700.00. Following the completion of the sale, the director now directly owns 2,056,931 shares of the company’s stock, valued at approximately $212,645,526.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Mock sold 647 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at $406,651. The disclosure for this sale can be found here. Insiders sold 109,954 shares of company stock valued at $11,533,976 in the last ninety days. Insiders own 15.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Oppenheimer raised Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price for the company in a research note on Tuesday, January 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a research note on Thursday, March 28th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Canaccord Genuity Group lifted their price objective on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research note on Friday, February 23rd. Finally, William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $126.49.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.